Table 1. Baseline characteristics of the study population.
| ALL patients n = 89 | NA-naïve n = 33 | NA-experienced n = 56 | p-Value | |
|---|---|---|---|---|
| Age(year) | 44 ± 11 | 49 ± 9 | 42 ± 11 | <0.01 |
| Gender (male%) | 70 (79%) | 22 (68%) | 48 (86%) | <0.05 |
| BMI (kg/m2) | 23 ± 3.1 | 23.4 ± 2.9 | 23 ± 3.2 | n.s. |
| ALT (IU/L) | 80 ± 136.2 | 82 ± 51.1 | 79 ± 166.1 | n.s. |
| AST (IU/L) | 63 ± 110.2 | 63 ± 33.6 | 63 ± 135.5 | n.s. |
| TBIL (μmol/L) | 20 ± 12.8 | 17 ± 5.8 | 21 ± 15.3 | n.s. |
| ALB (g/L) | 44 ± 3.2 | 42 ± 2.6 | 44 ± 3.3 | <0.01 |
| HBsAg (IU/mL) | 13374 ± 23703 | 8393 ± 13465 | 15692 ± 27019 | n.s. |
| HBeAg-positive | 67 (75%) | 18 (55%) | 48 (86%) | <0.01 |
| HBV-DNA (log10IU/ml) | 5.9 ± 1.8 | 6.2 ± 1.9 | 5.7 ± 1.7 | n.s. |
| Cirrhosis/chronic hepatitis | 13/65 | 5/28 | 8/37 | n.s. |
| Genotype (n = 76) | ||||
| B | 19 (25%) | 5 (19%) | 14 (28%) | n.s. |
| C | 52 (68%) | 19 (73%) | 33 (66%) | |
| Other | 5 (7%) | 1 (8%) | 3 (6%) | |
| Previous treatment with (peg) IFN | 17 (19%) | 5 (15%) | 12 (21%) | n.s. |
| Previous LAM treatment | ||||
| LAM-experienced | 21 (24%) | 21 (38%) | ||
| Prior history of LAM-resistance | 10 (11%) | 10 (18%) | ||
| Previous ADV treatment | ||||
| ADV-experienced | 43 (48%) | 43 (77%) | ||
| Partial virology response | 8 (9%) | 8 (14%) | ||
| Primary treatment failure | 32 (3%) | 32 (57%) | ||
| Previous treatment with LdT | 2 (2%) | 2 (4%) | ||
| Follow up (month) | 69 (60–75) | 57 (12–75) | <0.0001 | |
| LAM-experienced | 69 (60–75) | n.s. | ||
| ADV-experienced | 51 (12–72) | <0.0001 | ||
(ALT: alanine aminotransferase; AST: aspartate aminotransferase; TBIL: total bilirubin; ALB: albumin; ADV: adefovir dipivoxil; IFN: interferon; LdT: Telbivudine).